Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş et al. · The Lancet · 2021
Cited by 787 works. doi:10.1016/s0140-6736(21)00228-2
Authors
- Ahmet Sezer
- Saadettin Kılıçkap
- Mahmut Gümüş
- Igor Bondarenko
- Mustafa Özgüroğlu
- Miranda Gogishvili
- Hacı Mehmet Türk
- İrfan Çiçin
- Dmitry Bentsion
- Oleg A. Gladkov
- Philip R. Clingan
- Virote Sriuranpong
- Naiyer A. Rizvi
- Bo Gao
- Siyu Li
- Sue Lee
- Kristina McGuire
- Chieh-I Chen
- Tamta Makharadze
- Semra Paydaş
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Interpreting the significance of changes in health-related quality-of-life scores.
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial